There are 3 reasons why our price target had to be increased by 40% and could be raised even higher in the coming months. 1.New value for breast cancer indication 2.Nanomedicine getting major dollars 3.Firm gearing up for future trials

In recent months, a slew of activity has occurred in the nanomedicine, or nanobiotechnology industry, which bodes well for Nuvilex Inc. (OTCQB – NVLX), an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients. 

It is not often that a Company that has expertise in two distinct arenas can combine these two disparate groups to develop what could emerge as a unique and ground-breaking cancer treatment method.

With few other low-cost solutions to the problem available and only ever-rising costs looming, Inscor (OTCPK – IOGA) has an opportunity to effect real change in government financial management and generate significant revenue for itself in the coming years.

Until the arrival of Plandai Biotechnology, Inc. (OTCQB – PLPL), even many wellness pundits were unaware that substantial increases in bioavailability and effectiveness of some products, like green tea extracts, were possible and would change the face of the industry.

As broad development of its proprietary live-cell encapsulation platform delivery system progresses, it is possible that “Big Pharma” takes notice of Nuvilex Inc. (OTCQB – NVLX).

On May 14, 2013, Goldman Small Cap Research published an Article on Nuvilex, Inc. (OTCQB – NVLX).

Today we are issuing an updated report on LIG Assets (LIGA). LIG Assets may be one of the most successful opportunistic investors and financiers of its size and its strategy could result in $3-4M in net profit this year. Such a return is 4x the current market cap, making LIG’s share price a rare bargain.